Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
JOHNSON & JOHNSON (CIK 200406) reported $652.4M across 16 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: PTGX ($258.1M, 39.57%), NBTX ($173.6M, 26.61%), MGTX ($57.5M, 8.82%), RAPP ($55.8M, 8.56%), CVRX ($38.1M, 5.84%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc. | $258.1M | 39.57% | 2.4M | Hold |
| 2 | NBTX | Nanobiotix S.A. | $173.6M | 26.61% | 5.6M | Hold |
| 3 | MGTX | MeiraGTx Holdings plc | $57.5M | 8.82% | 6.6M | Hold |
| 4 | RAPP | Rapport Therapeutics, Inc. | $55.8M | 8.56% | 1.8M | Hold |
| 5 | CVRX | CVRx, Inc. | $38.1M | 5.84% | 4.0M | Hold |
| 6 | CTNM | Contineum Therapeutics Inc. | $25.8M | 3.96% | 2.0M | Hold |
| 7 | LEGN | Legend Biotech Corporation | $14.7M | 2.26% | 814,586 | Hold |
| 8 | XNCR | Xencor, Inc. | $9.0M | 1.38% | 748,062 | Hold |
| 9 | PRCT | Procept BioRobotics Corporation | $9.0M | 1.37% | 357,939 | Hold |
| 10 | FATE | Fate Therapeutics, Inc. | $4.1M | 0.62% | 3.4M | Hold |
| 11 | NMRA | Neumora Therapeutics, Inc. | $3.6M | 0.55% | 1.8M | Hold |
| 12 | RLYB | Rallybio Corporation | $1.4M | 0.21% | 152,901 | New |
| 13 | VOR | Vor Biopharma, Inc. | $958,579 | 0.15% | 53,732 | Hold |
| 14 | LAB | Standard BioTools, Inc. | $286,791 | 0.04% | 311,967 | Hold |
| 15 | NNOX | Nano-X Imaging Ltd. | $189,668 | 0.03% | 83,554 | Trimmed |
| 16 | ACET | Adicet Bio, Inc. | $155,125 | 0.02% | 22,779 | Hold |
| 17 | LYEL | Lyell Immunopharma, Inc. | $0 | 0.00% | 0 | Exited |
| 18 | RLYB | Rallybio Corporation | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-03-31